Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Global Partners LP(GLP) MarketBeat·2024-07-01 22:39
Eli Lilly and Company Today LLY Eli Lilly and Company 434.34 ▼ 812.72 Add to Watchlist Global pharmaceutical giant Eli Lilly & Co. NYSE: LLY has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. Mounjaro is prescribed for Type 2 diabetes but is often used off-label for weight loss. Zepbound is prescribed for obesity treatment. The active ingredient in both is Tirzepatide. Lilly sub ...